In this issue of Blood, Szydlowski and colleagues further characterize the components of the proapoptotic pathway that is repressed by the tonic BCR signal. 1 They show that inhibition of the tonic BCR signal results in increased activation of FOXO1 and increased expression of its target genes, including the proapoptotic BCL2 family member, BCL2L11, and the cell-cycle inhibitor p27. Importantly, they also show that depletion of FOXO1 by RNA interference abrogates R406-induced cytotoxicity in DLBCL cells with tonic BCR signaling, but not in cells with chronic-active BCR signaling. The reduced sensitivity to R406-induced apoptosis in cells with depleted FOXO1 is associated with reduced induction of HRK, further suggesting that FOXO1 is the critical mediator of the proapoptotic pathway that is repressed by the tonic BCR signal. Finally, Szydlowski et al investigate the mechanism through which FOXO1 regulates HRK expression and show that it involves inactivation of the HRK transcriptional repressor DREAM through a caspase-dependent process that is activated by transcriptional targets of FOXO1. These findings are important because they provide further support for clinical testing of BCR signaling inhibitors not only in DLBCL with chronic active BCR signaling, but also in DLBCL that is dependent on tonic BCR signaling. A crucial issue for future studies will be to determine what type of BCR signaling inhibitor would be most appropriate for patients belonging to each of the 2 DLBCL subsets with an activated BCR pathway. Based on the results of this study and the study of Chen et al, 5 both SYK and PI3K inhibitors would be expected to be active in BCRdependent DLBCL, independently of the mechanism that activates the BCR pathway. Although clinical data are scarce, the SYK inhibitor fostamatinib, which is the prodrug of R406, has already shown clinical activity in patients with DLBCL, with 22% (5/23) of the treated patients responding to treatment. 6 A similar response rate was observed in the phase 1/2 clinical trial with ibrutinib in patients with relapsed/refractory DLBCL, with 25% (20/80) of patients responding to treatment. 4 Interestingly, however, no patient with DLBCL responded to treatment with the selective PI3Kd inhibitor idelalisib in the phase 1 study of relapsed/refractory non-Hodgkin lymphoma. 7 The lack of responses in that study is probably a result of the small number of enrolled DLBCL patients (n 5 9), but may also indicate that targeting PI3Kd is insufficient to completely block the tonic BCR signal. This possibility needs to be considered in view of findings in murine models suggesting that the tonic BCR signal can be mediated by either PI3Ka or PI3Kd, whereas antigen-dependent signaling is mediated only by PI3Kd.
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Moreover, clinical responses have been observed in DLBCL patients with the dual PI3K-d/PI3K-a inhibitor BAY 80-6946, 10 indicating that both PI3K isoforms could be involved in transducing BCR signals in DLBCL.
Another important question that still remains unresolved is how to identify DLBCL patients who are most likely to respond to treatment with BCR signaling inhibitors. The use of the ABC DLBCL gene-expression signature has been proposed as a biomarker to enrich for patients with chronic active BCR signaling that are more likely to be sensitive to ibrutinib treatment, based on the higher response rate in ABC than GCB DLBCL (37% vs 5%, respectively). 4 In the study by Szydlowski et al, expression of FOXO1, which was absent in 20% of the tumors, was proposed as a potential biomarker to identify patients who should be resistant to SYK or PI3K/AKT inhibitors. Although these biomarkers are undoubtedly valuable, the majority of patients that they would select would still be expected to be unresponsive to treatment. Therefore, further efforts to identify biomarkers for tonic and chronic BCR pathway activation will be essential for the development of Origin of stem cells in the BM niche: new clues from mastocytosis In which kind of cell does the D816V mutation arise? The following possibilities should be considered (see figure) . First, HSCs and BMSCs may be derived from a common stem/progenitor cell. If a mutation were to take place in this hypothetical stem cell, both hematopoietic and the mesenchymal cells would be expected to harbor the genetic defect. Although the existence of such "super" stem cells in the adult hematopoietic niche continues to be debated, there is a plausible candidate-the very small embryonic-like stem cells. These cells appear to have a differentiation potential that goes beyond the well-established lineage restriction of HSCs and BMSCs. 7 Another possibility is that the mutation arises in a hematopoietic cell progenitor that can give rise to stromal cells. This may be a process that is analogous to the creation of myeloid-derived fibrocytes, 8 many of which eventually stop expressing CD45, obscuring their hematopoietic cell origin. Although reports suggesting that cells might arise in this way are few in number, there is evidence that this sort of transformation could occur.
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Those scientists who are averse to the idea that mast cells and BMSCs might have a common precursor are left with a somewhat unattractive alternative-that c-kit mutations in the 2 cell populations occurred independently. If the putative mutation takes place in a BMSC progenitor, most sorts of BMSCs would be expected to have it. If it occurred in a more differentiated cell, the resulting clone might have a more narrow set of functions and resemble skeletal stem cells, pericytes, CAR cells, 10 stromal fibroblasts, etc. It would certainly be interesting and important to study clonally selected mutant MSCs in more detail.
The existence of such cells would raise another possibility-that BMSCs could have gain-of-function mutations in diseases that share some similarities with mastocytosis, but lack mast cell pathology. Again, analysis of single cell-derived BMSC colonies or single-cell PCR studies of fresh uncultured BM-derived MSCs could readily address the questions listed here. The methods available to us have become so powerful that we should no longer be constrained by dogma. Rather than debating hypotheses like the ones we have outlined in this commentary, we should simply test them. It would be exciting to rewrite our textbooks.
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In this issue of Blood, Aghourian et al demonstrate that growth arrest-specific protein 6 (Gas6) contributes to tumor-induced venous thromboembolism (VTE) by promoting the expression of platelet-activating prostaglandin E 2 (PGE 2 ) in the endothelium. Aghourian et al unravel a novel link between tumor-mediated thrombosis and Gas6, which may provide yet another explanation for the procoagulant phenotype of many tumors. Gas6 is a vitamin K-dependent ligand for the receptor tyrosine kinase family comprising Tyro3, Axl, and Mer (TAM). It has the ability to bind to negatively charged phospholipids, such as phosphatidylserine exposed on apoptotic cells, which allows Gas6 to bridge TAM-expressing phagocytes to apoptotic cells thus potentiating phagocytosis. The Gas6-TAM system is a crucial anti-inflammatory signaling complex in immune cells, in addition to which it acts as a prosurvival factor, not only in tumors but also in the endothelium. Despite being homologous to the anticoagulant protein S, Gas6 has been shown to act mainly as a procoagulant factor. Gas6 2/2 mice are protected against lethal venous thrombosis, explained by a weakened platelet aggregation response 3 and by decreased tissue factor expression in the endothelium. 4 In the presence of endothelium-derived Gas6, tumor cells induce phosphorylation of Erk1/2 in endothelial cells, leading to an upregulation of Ptges production. Ptges produces PGE 2 from prostaglandin H 2 (PGH 2 ), which, on secretion, interacts with the EP3 receptor on platelets to trigger platelet activation and promote thrombosis. Whether the effects mediated by Gas6 are due to an interaction of Gas6 with the tumor cell or through an autocrine signaling in the endothelial cell is still unknown.
